Omega-3 Pufa and Aspirin as Adjunctive Therapy in Treatment of Smoker Patients With Stage Iii Periodontitis

Alexandria University

Status

Completed

Conditions

Periodontitis

Diabete Mellitus

Treatments

Other: Omega-3 PUFA and Aspirin and doxycycline as adjunctive therapy to (SRP)

Other: scaling and root planning (SRP)

Other: Omega-3 PUFA and Aspirin as adjunctive therapy to (SRP)

Study type

Interventional

Funder types

Other

Identifiers

NCT07385300

0710-06/2023

Details and patient eligibility

About

Background: Smoking reduces the effect of non-surgical periodontal therapy, a host modulation regimen consisting of omega-3 polyunsaturated fatty acids (ω-3 PUFA) supplementation with low-dose aspirin (ASA) with or without systemic doxycycline has been proposed to improve treatment response.

The Aim of the study is to explore the clinical effects of orally administered omega-3 PUFA and ASA with or without systemic doxycycline with periodontal debridement in treatment of smoker individuals with stage III periodontitis.

Enrollment

45 patients

Sex

All

Ages

35+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Smoker patients who smoke ≥ 10 cigarettes per day.
Stages III, Grades C periodontitis with at least one site with PD≥6 and CAL ≥5 mm.

Exclusion criteria

Scaling and root planning in the previous 6 months(that may confound the effect of treatment)
Antimicrobial therapy in the previous 6 months(that may confound the effect of treatment)
Chronic systemic diseases that may have an impact on periodontitis progression (diabetes mellitus).
Systemic diseases that may contraindicate aspirin or doxycycline taking (kidney and liver diseases)
Allergy to doxycycline
Long-term usage of medications that may impair periodontal health
Allergy to fish/seafood